AZ's cediranib falls short again in ovarian cancer combinati...

AstraZeneca and Merck & Co’s latest attempt to revive an old pipeline drug cediranib has failed as it did not improve survival compared with chemotherapy in advanced ovarian cancer, in

Staying on the cutting edge of oncology advances

Rapidly-changing treatment landscapes in diseases like lung cancer pose challenges for medical education providers, who need to be more adaptable than ever.

Sanofi gets first OK for isatuximab for myeloma, challenging...

Gilead to buy immuno-oncology firm Forty Seven for $4.9bn

Gilead is to buy immuno-oncology firm Forty Seven for $4.9 billion, adding an antibody targeting several blood cancers to its research pipeline.

Roche hops on Bicycle’s drug discovery platform for cancer

PREDiCT: Imaging Modalities for Oncology Drug Development

Guiding Your Strategic Approach of Multimodal Imaging